Protocol Ledger

NCT06191263 · Phase II · RECRUITING

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Interventional Phase II clinical trial protocol NCT06191263 sponsored by Ryvu Therapeutics SA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-05 Enrollment: 98 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06191263
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06191263
Protocol FieldVerified Registry Value
NCT IdentifierNCT06191263
Consolidated Lead SponsorRyvu Therapeutics SA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment98 participants (ESTIMATED)
Registered Start Date2024-01-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06191263
Hospital Research SiteLocationSite Profile
Institut Paoli-CalmettesMarseille, FranceOpen Hospital Dossier ->
Centre Henri BecquerelRouen, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI